User profiles for Robin Marlow
 | Robin MarlowConsultant in Paediatric Emergency Medicine / Honorary Senior Lecturer Verified email at bristol.ac.uk Cited by 801 |
[HTML][HTML] Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United …
Background There is an urgent public health need to evaluate disease severity in adults
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
hospitalised with Delta and Omicron SARS-CoV-2 variant infections. However, limited data exist …
[HTML][HTML] Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative …
Background On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination authorised for
UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine …
UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine …
Association of use of a meningococcus group B vaccine with group B invasive meningococcal disease among children in Portugal
Importance A 4-component meningococcus group B vaccine (4CMenB) is the only vaccine in
use to prevent group B invasive meningococcal disease in young children, but no matched …
use to prevent group B invasive meningococcal disease in young children, but no matched …
[HTML][HTML] Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination
…, A Banzhoff, C Azzari, P De Wals, R Marlow… - Journal of Infection, 2021 - Elsevier
Objectives 4CMenB is a broadly protective vaccine against invasive meningococcal capsular
group B disease (MenB IMD). Licensed worldwide based on immunogenicity and safety …
group B disease (MenB IMD). Licensed worldwide based on immunogenicity and safety …
Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalisations in elderly and frail adults: a single centre test …
Background: On 8 th December 2020, deployment of the first vaccine against SARS-CoV-2
authorised for UK use, the mRNA-based vaccine BNT162b2, began, followed by the …
authorised for UK use, the mRNA-based vaccine BNT162b2, began, followed by the …
[HTML][HTML] Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B. 1.617. 2) and …
Background Whilst other studies have reported the effectiveness of mRNA vaccination against
hospitalisation, including emergency department or intensive care admission, few have …
hospitalisation, including emergency department or intensive care admission, few have …
[HTML][HTML] Incidence of community acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A prospective cohort study
Background The emergence of COVID-19 and public health measures implemented to
reduce SARS-CoV-2 infections have both affected acute lower respiratory tract disease (aLRTD) …
reduce SARS-CoV-2 infections have both affected acute lower respiratory tract disease (aLRTD) …
Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in the UK vaccination programme, during the Spring-Summer (monovalent vaccine) and Autumn …
Background Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine
formulations against SARS-CoV-2 infection is an urgent public health priority. A precise …
formulations against SARS-CoV-2 infection is an urgent public health priority. A precise …
Risk of herpes zoster after exposure to varicella to explore the exogenous boosting hypothesis: self controlled case series study using UK electronic healthcare data
Objective To assess the magnitude and duration of any hypothesised protective effect of
household exposure to a child with varicella on the relative incidence of herpes zoster in adults. …
household exposure to a child with varicella on the relative incidence of herpes zoster in adults. …
[HTML][HTML] Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn …
Background Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine
formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of …
formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of …
